Vascular Biogenics Ltd

NASDAQ:VBLT   3:59:44 PM EDT
1.23
+0.02 (+1.65%)
Other Pre-Announcement

VBL Therapeutics Reports Third Quarter 2020 Financial Results And Provides Corporate Update

Published: 11/16/2020 12:19 GMT
Vascular Biogenics Ltd (VBLT) - Vbl Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Vascular Biogenics Ltd - Expects Cash, Cash Equivalents Among Others to Be Sufficient to Fund Operating Expenses and Capex Needs Into Q3 of 2022.
Vascular Biogenics Ltd Qtrly Revenues Were $193 Thousand Versus $79 Thousand.
Vascular Biogenics Ltd Qtrly Loss per Ordinary Share $0.12.
Vascular Biogenics Ltd - Investigator Sponsored Vb-111 Phase 2 Studies, in Rgbm is on Track for Initiation.